Yves right here. Yours really has had greater than just a little expertise with weight loss program, dietary complement, and different drugs fads. When the peptide buzz began a couple of years in the past, I paid little consideration as a result of the promised advantages had been in “too good to be true” terrain.
This text offers much more trigger for pause. Snake-oil-salesman-in-chief, RFK, Jr, is throwing his weight behind a peptide, BPC-157, developed by a medical researcher who makes miracle claims for its advantages with nearly no proof to again it up. Worse, the analysis was carried out in Zagreb, Croatia, beginning within the Nineteen Seventies. I visited Zagreb in 1997. Completely no means would I take into account something within the medical class out of Zagreb based mostly on what I noticed then. Not solely was it clearly markedly behind the West just about throughout the board, however the high quality requirements within the supposedly top-drawer lodge I used and the restaurant the place I used to be taken had been poor. Against this, in 2000, I had a flare up of an orthopedic challenge after I was in Bangkok. The hospital I went to was spartan-looking however very clear and the physician gave me an excellent examination and an efficient therapy. So my view about Zagreb doesn’t mirror a prejudice in opposition to outside-the-first-world establishments.
In 1975, in a medical college classroom in what was then the Socialist Federal Republic of Yugoslavia, Predrag Sikiric had an concept that he has pursued for greater than 50 years.
His obsessive quest would take him from gastroenterology clinics to worldwide scientific conferences, outline his profession as an instructional, and seize the eye of world pharmaceutical corporations. It could ultimately develop into one a part of the Make America Wholesome Once more motion’s effort to reform federal drug regulation.
This story is being co-published with STAT Information, and was supported by the Pulitzer Middle.
However on the time, Sikiric was only a second-year medical pupil on the College of Zagreb Faculty of Drugs in Croatia, listening to a lecture in regards to the adrenal glands and the physique’s response to emphasize. Overwhelming stress, he knew, may injury the liner of the abdomen. Absolutely, he thought, the abdomen itself should produce a substance that enables the physique to struggle again — a form of anti-stress chemical. It could be pure and freed from unintended effects, he imagined. If somebody may discover it, they might have their palms on a outstanding treatment.
The concept was lofty. To many scientists, he acknowledges, it nonetheless sounds inconceivable. But eight years later, on the outset of his Ph.D., Sikiric managed to encourage a small band of colleagues to hitch him within the seek for this hypothetical compound, which he dubbed Substancija Boze Pomozi, or, roughly, “substance God assist me.”
First, they wanted gastric juice. Plenty of gastric juice. Sikiric mentioned he and his workforce collected the extremely acidic abdomen fluid from gastroenterology clinics and emergency rooms, the place it was a waste product of some medical procedures. As a part of the search, he mentioned, he usually traveled to a hospital within the seaside metropolis of Break up, the place he obtained the juice in bottles and plastic luggage. A doctor pal in Bosnia and Herzegovina despatched near-daily shipments by bus. Some workforce members visited pig slaughterhouses, the place the GI tract is often faraway from the meat to stop contamination. Sikiric remembers the juice generally harbored rats that had been caught and eaten by the pigs of their closing hours.
They introduced all of it again to the College of Zagreb and saved it in a communal fridge within the Division of Pharmacology. Often a glass bottle would crack and emit a rancid odor. However Sikiric had the unwavering assist, he recollects, of the division chief, so he pressed forward.
The group spent years subjecting the gastric juice to a particular type of screening course of. The main points are proprietary, Sikiric mentioned, and he declined to share them. However, in interviews, he and a colleague described the final course of. The workforce’s chemists would isolate compounds from the juice, after which Sikiric would take a look at these compounds utilizing animal experiments. He repeated this process many occasions, homing in on what he needed.
Sikiric mentioned that in 1989, they discovered what they had been in search of: a substance that appeared to own a variety of therapeutic results to assist the physique return to regular after it was subjected to emphasize. That substance was a protein, and from it, they recognized a smaller substance that they believed was the lively precept, or the a part of the protein liable for producing the therapeutic advantages.
This piece of protein, a kind of molecule known as a peptide, was simply 15 amino acids lengthy. Sikiric dubbed it “BPC 157.” In time, it turned a type of bootleg panacea, bought by gray-market distributors to bodybuilders and biohackers, even because it struggled to win the approval of mainstream drugs.
As we speak, Sikiric and his workforce describe BPC-157 as an all-purpose therapeutic compound. Laboratory experiments with animals and cell cultures, they write, counsel the peptide might deal with all the pieces from muscle accidents to glaucoma to ulcers. And few if any unintended effects have been documented within the scientific literature.
Nonetheless, the place some see a promising drug, others see huge claims backed by little proof. Many medical researchers warn that there’s scant printed knowledge exhibiting whether or not — or how — the peptide truly works in human beings. Some have additionally raised pointed questions on whether or not BPC-157 originates within the human physique in any respect. Sikiric’s workforce, they are saying, might have made an sincere mistake all these years in the past, by accident yielding a sequence of amino acids that’s not truly produced within the physique
In Sikiric’s workplace, a jar with the label “BPC” sits on a shelf.Visible: Sara Talpos for Undark
Now the peptide is on the coronary heart of a polarized debate in the US, one which raises a core query about how the Meals and Drug Administration ought to manage medication: Ought to common People be capable to entry unapproved substances like BPC-157? Since 1962, with the intention to convey a drug to market, producers have been required to run managed trials in human beings to gauge security and effectiveness. That vetting has not occurred for Sikiric’s peptide, and federal regulation technically restricts its sale.
Well being and Human Companies Secretary Robert F. Kennedy Jr., nonetheless, has mentioned that it’s not the FDA’s position to stop individuals from accessing experimental drugs. As an alternative, he says, People ought to be capable to resolve for themselves whether or not to attempt an unapproved remedy. In the case of unapproved peptides like BPC-157, he has made an extra argument: These substances are already on the grey market, elevating the chance that somebody could also be harmed by a mislabeled or contaminated product. It could be safer to permit individuals to get these unapproved medicines from a licensed pharmacy, Kennedy has argued.
This summer time, an FDA advisory committee will take into account permitting pharmacies to compound and promote seven unapproved peptides, together with BPC-157. In an April submit on X, Kennedy wrote that for every peptide, the committee will weigh the “full scientific, pharmacological, and security proof.” The subsequent day, he asserted that these peptides are like dietary supplements, and due to this fact won’t have to undergo scientific trials.
“It is a courageous new world,” mentioned Jacob Sherkow, a professor of legislation and drugs on the College of Illinois. For many years, the FDA has handled injectable peptides, like insulin, as medication. Now, with this potential pivot, the strategy is extra “‘You understand, we’re going to permit a few of these to go ahead with none rigorous scientific proof base,’” he mentioned.
Within the case of BPC-157, nearly all of proof comes out of Sikiric’s lab in Zagreb. However the full historical past of the peptide’s growth has not been written — partially as a result of Sikiric has by no means printed some particulars in regards to the discovery and human testing of BPC-157, and partially as a result of he has hardly ever chosen to go on-the-record with English-language reporters.
In Might, although, he granted Undark entry to his workforce on the College of Zagreb Faculty of Drugs, together with intensive interviews with him, his collaborators, and greater than 20 present and former Ph.D. college students, most of whom proceed to work on BPC-157. Many of those interviews happened in Sikiric’s workplace, which is lined with houseplants, a Croatian flag, and pictures of Sikiric with colleagues. In 2020, an earthquake broken the constructing that homes his fundamental laboratory, so packing containers and lab gear had been piled up within the workplace’s corners.
In the course of the go to, Sikiric was demonstrably involved that the story of his decades-long undertaking, which is now embedded in a second of reckoning for drug regulation on the opposite facet of the globe, be instructed as he sees it. He usually turned to his PowerPoint displays to clarify the science. On a phenomenal Saturday afternoon, whereas Zagreb was full of individuals turning out for Europe Day celebrations, Sikiric sat down in his workplace.
“So, we’re right here,” he mentioned, pointing to a slide. “It’s important to make sure that you get it.”
Sikiric, who’s now 72, nonetheless works full days, sometimes with out taking a break to eat. His colleagues and college students describe him as hyper-focused, emotional, and never significantly considering standing or titles. “He didn’t play that standard educational sport of ‘respect hierarchy,’” recalled one in all his former Ph.D. college students. “He was identical to ‘that’s bullshit — and let’s do the work.’”
Sikiric grew up in Zagreb, the oldest of 4 kids, on a avenue lined with house properties courting again to the Austro-Hungarian Empire. His father, he mentioned, was a outstanding legal professional who specialised in patent points, and an outspoken critic of the Communist social gathering who narrowly escaped execution after World Struggle II. He was usually put in jail, Sikiric recollects, together with each time the Yugoslav President, Josip Broz Tito, got here to Zagreb. Sikiric took to calling this “free native lodging.”
When Sikiric entered medical college within the Nineteen Seventies, he recalled, some lecture supplies had been solely obtainable on the black market. He requested the professors to jot down out the category content material, after which he helped arrange a bunch of scholars who printed the fabric with a hand-cranked machine. Later, as a younger physician, Sikiric labored in rural areas of the nation, the place he generally needed to ration medical gear and personnel.
Within the Eighties, when the work on gastric juices started, funding for Croatian scientists was restricted, Sikiric mentioned, and there have been few alternatives to interact with Western researchers. In the direction of the top of that decade, Sikiric printed a number of papers based mostly on his Ph.D. analysis in a European pharmacology journal. That work got here throughout the desk of a professor who was then at Harvard, Sandor Szabo, who despatched Sikiric a letter inviting him to a scientific convention in Canada held in 1989.
The expertise opened Sikiric as much as a world of researchers within the physique’s response to emphasize. In 1936, endocrinologist Hans Selye had printed a landmark paper in Nature, describing what number of completely different harms — toxins, harm, and chilly temperature — can set off the identical organic stress response. Some 40 years later, his former pupil, a researcher named André Robert, confirmed that hormone-like substances known as prostaglandins may defend the abdomen lining from harm. He known as that course of cytoprotection. Szabo, one other former Selye pupil, constructed on these findings to indicate that cytoprotective compounds work, partially, by defending the blood vessels simply beneath the abdomen lining. This helps keep circulation, which in flip results in much less tissue injury and quicker therapeutic.
Sikiric believed that BPC-157 was cytoprotective, too. He took the idea one step additional: As an alternative of finding cytoprotection primarily within the abdomen, or within the GI tract, he theorized that the peptide may protect blood vessels — and thus defend tissue — throughout each organ of the physique.
It was a promising time to construct worldwide collaborations. Partitions had been falling throughout Japanese Europe. A way of freedom was within the air, Sikiric recollects. However for Croatia, it was clear there could be no independence with out struggle.
Within the years main as much as the collapse of Yugoslavia, Sikiric had modified the identify of the substance to BPC, an acronym that carried two meanings directly: Bože Pomozi Croatia, “God Assist Croatia,” and, within the scientific literature, “Physique Safety Compound.” Ultimately, they added 157 to the identify of the peptide, as Sikiric mentioned that July 15, 1990 had been rumored — wrongly, it turned out — to be the date when the nation was going to declare independence.
When the declaration got here the next summer time, struggle broke out between the younger state and Serbian-controlled forces against Croatian independence. Many medical college school members had been engaged within the struggle indirectly, recalled Sven Seiwerth, a pathology professor on the college who has labored on the BPC-157 undertaking because the Eighties. He volunteered to work as a medical physician on the entrance strains. On the time, he had a spouse and two younger kids. “It was only a matter of surviving,” he mentioned.
In 1992, different nations started to acknowledge Croatia as an impartial state, and contained in the nation, political winds had been lastly on the workforce’s again, Sikiric mentioned. He had one huge stroke of luck: Zagreb was residence to a serious pharmaceutical firm, PLIVA, which was having fun with a windfall from growing the antibiotic azithromycin.
The corporate was in search of its subsequent blockbuster. In 1993, Sikiric mentioned, he signed a contract with PLIVA. The corporate started researching BPC-157, working alongside college researchers and an American pharmaceutical firm known as Parke-Davis.
They received some promising outcomes. In a examine from 1995, for instance, researchers at a Parke-Davis facility in Ann Arbor, Michigan, administered the substance to rats and located that it helped defend the rodents’ colons from harsh chemical compounds administered into their intestines an hour later. Research by a workforce of researchers at PLIVA and the College of Pécs in Hungary discovered an identical protecting impact once they examined items of the peptide in freshly remoted rat abdomen cells.
PLIVA additionally started testing the drug in people. Within the early 2000s, the corporate held two early-stage trials to see if BPC-157 may assist deal with ulcerative colitis. Researchers by no means printed the total outcomes, though a quick write-up in 2005 reported that the second trial discovered a optimistic impact however that it didn’t attain statistical significance.
Accounts differ as to what occurred subsequent. In accordance with Sikiric, PLIVA scientists had been prepared to maneuver ahead with a Part 3 trial, along with new trials to check the impact of the peptide on wound therapeutic. However in 2006, the corporate’s analysis institute was bought to GlaxoSmithKline. In the meantime, the remainder of PLIVA, which was targeted on generic medication, was acquired by Barr Prescribed drugs that very same yr. Barr was then acquired by Teva Prescribed drugs in 2008.
The BPC-157 undertaking was transferred to GSK, however the firm dropped it. That’s not as a result of the drug didn’t work or was discovered to be unsafe, Sikiric mentioned, however as a result of the individuals at GSK had been wedded to their very own tasks. He believes GSK deserted a promising drug.
“When an enormous firm takes over just a little firm, they select the bits that they suppose match what they need, and depart the remainder,” mentioned Michael Parnham, who was a senior scientific adviser at PLIVA on the time of the acquisition by GSK.
Parnham was recruited to PLIVA in 1998, and he mentioned he was skeptical of the BPC-157 undertaking from the get-go. For one factor, it got here with an uncommon licensing settlement by which PLIVA had agreed to convey the drug to scientific trials, he mentioned. (Sikiric says the settlement was to take all of it the way in which to market, although he declined to indicate the settlement to Undark.)
Parnham additionally discovered the experimental outcomes underwhelming. At PLIVA, his workforce printed two papers evaluating BPC-157’s means to heal wounds in rats in opposition to the usual remedy. BPC-157, they noticed, promoted the early growth of granulation tissue, which is made up of cells and new blood vessels that assist restore. They wrote that the peptide appeared to stimulate, both immediately or not directly, a particular gene concerned within the physique’s response to harm.
But it surely barely outperformed an current drug. “Within the arduous world of drug advertising and drug gross sales, it might have been extraordinarily troublesome to persuade individuals, ‘Look, we’ve received one thing higher,’” Parnham mentioned.
Parnham additionally expressed hesitation about the way in which Sikiric introduced the information, describing him as wielding flashy slides with an excessive amount of certainty, “like a advertising pitch.”
On the finish of 2009, the licensing rights to BPC-157 had been returned to Sikiric, together with all the knowledge that PLIVA had generated. He and his workforce have continued to analysis the peptide on their very own, largely doing research in rodents. A handful of different groups — together with in Taiwan, South Korea, China, and Turkey — have additionally printed research, all reporting optimistic outcomes and documenting few, if any, unintended effects.
Not everybody sees the dearth of unintended effects as a optimistic: “Something with out unintended effects might be not very lively,” mentioned Parnham. And there nonetheless isn’t a lot in the way in which of human knowledge. A scientific trial, begun in Tijuana round 2015 and sponsored by a Croatian firm that lists Sikiric as a partial proprietor, is listed as canceled in a U.S. authorities database. In a 2025 evaluate, Sikiric and his workforce report that the examine discovered the peptide was “protected and well-tolerated,” however they haven’t printed the information.
A technology in the past, the story may need ended there. However based on Luke Turnock, a criminologist within the U.Ok., round 2010, in on-line boards, bodybuilders started speaking about peptides, and a few appear to have discovered their solution to Sikiric’s scientific papers. These gym-goers, Turnock mentioned, discovered easy methods to supply peptides like BPC-157 from suppliers in China. Quickly, a thriving grey market emerged, with BPC-157 as one in all its stars.
Sikiric can’t bear in mind precisely when he first discovered that bodybuilders had been utilizing BPC-157. However he does recall what he felt: happiness, like a guardian watching their baby develop up and are available into its personal.
“What’s the important function of the drug?” he requested. “To be helpful for the individuals.”
BPC-157’s use has since unfold from bodybuilders to biohackers to sufferers with unmet medical wants. It’s now broadly bought on-line, usually marketed as a pure substance, produced by the human physique, that has been spurned by pharmaceutical corporations however found by medical outsiders.
It has additionally been picked up by the MAHA motion. On an episode of his “Final Human Podcast” this previous December, Gary Brecka, a wellness entrepreneur and a key determine within the MAHA motion, ticked off a half dozen ailments and situations that he believes BPC-157 can deal with. It and different unapproved peptides, he recommended to his visitor, then-FDA commissioner Marty Makary, have produced “astounding outcomes.”
On a day in March, Anna Mapp sat down at a desk in her workplace with a unfastened pile of printouts. On the request of Undark, the College of Michigan chemist — and present president of the American Peptide Society — had reviewed a number of BPC-157-related paperwork, together with the Croatian workforce’s patent for isolating BPC-157’s guardian protein.
Sitting throughout from giant papier-mâché molecules made by former college students, Mapp expressed shock on the restricted quantity of element within the patent. Even the protein’s molecular weight isn’t pinned down. “There was no demonstration that I may inform that it was a single pure remoted substance,” mentioned Mapp. Had the workforce remoted only one protein, or a mix of various substances?
It’s additionally uncommon that the total protein’s sequence was by no means printed, she mentioned, describing the omission as unacceptable underneath right now’s requirements of scientific apply. With out the total sequence, it’s inconceivable to breed the unique work, a vital type of quality-control for scientists.
And as for the peptide itself, genetic materials that codes for its distinctive amino acid sequence hasn’t been discovered within the human genome or intestine microbiome. “That’s troubling,” mentioned Mapp.
It’s additionally not clear how the peptide would act on the physique, she famous — a degree raised by a number of different researchers. “The overwhelming majority of peptides require receptors to work,” Patricia Brubaker, a peptide scientist on the College of Toronto, wrote in an e-mail to Undark. Most peptide medication work by binding to a receptor on the floor of cells, a course of that then initiates adjustments in how the cell behaves. However it seems that no one has definitively discovered a devoted BPC-157 receptor, and Sikiric hasn’t targeted his analysis on discovering one.
Anna Mapp, a chemist on the College of Michigan and present president of the American Peptide Society, reviewed a number of BPC-157-related paperwork at Undark’s request. Mapp mentioned it’s uncommon that the total protein’s sequence has by no means been printed, and she or he questioned whether or not it’s truly produced by the physique in any respect.
All of that proof, taken collectively, has led Mapp and different researchers to query a key element of BPC-157’s origin story: They’re not satisfied it’s truly produced by the physique in any respect.
Sandor Szabo, Sikiric’s longtime colleague, co-authored a 2017 paper that presents BPC-157 as a promising drug for the prevention and therapy of ulcers. The paper, on the similar time, outlines the lacking particulars that one would anticipate for a pure substance. If the peptide had been made within the physique, Szabo and his colleagues wrote, one would anticipate that over the course of a long time, researchers would have recognized the gene that encodes it, the cells that make it, the receptors that it interacts with, and the degrees at which it happens within the physique.
Maybe, he says now, the unique workforce misinterpreted an amino acid sequence a few years in the past. On the time, strategies for performing chemical analyses weren’t well-refined.
Nonetheless, Szabo mentioned he has little doubt that the substance can defend the abdomen and small gut. He pointed again to the a number of teams, together with his personal, which have reproduced the findings in cell cultures and rodents.
It might not be a pure compound, he mentioned. “So long as it really works and has no unintended effects, who cares?”
One night, after most school had left the constructing, Sikiric was nonetheless at his laptop. On a wall to his proper was a print of the Virgin Mary, her face partially obscured by empty lab provide packing containers. Beside them, the red-tiled rooftops of Zagreb had been seen via a window.
Sikiric clicked via a couple of slides till he reached one containing a passage about cytoprotection, from a 1979 paperby Robert, the researcher who helped delivery the sector. It’s a paper that has develop into a north star for Sikiric’s work, and he invoked it now to defend his undertaking: The passage doesn’t point out receptors, Sikiric identified, suggesting to him that Robert didn’t view them as important for cytoprotection.
Over the previous seven months, in dozens of conversations with Undark, Sikiric has laid out his view of how BPC-157 capabilities contained in the physique. His analysis, he says, signifies that the peptide works, partially, by reversing injury to blood vessels and by serving to regulate ranges of nitric oxide, a molecule that relaxes blood vessels and helps forestall hypertension.
Predrag Sikiric and Sven Seiwerth sit within the pathology constructing of the College of Zagreb in Might 2026. The pair have collaborated on the BPC-157 undertaking for greater than 40 years. They estimate that 100 or extra present and former Ph.D. college students have labored with them. Visible: Igor Nobilo for Undark
As Sikiric tells it, there is no such thing as a different substance proper now that compares with BPC-157. He says the peptide promotes blood clotting when that’s what’s wanted — and blood thinning when needed. It might stimulate the creation of recent blood vessels when the physique wants them to heal from harm, however it doesn’t create new blood vessels that may stimulate tumor development. (Sikiric disagrees vigorously with researchers who say it’s believable the peptide may trigger most cancers.)
He additionally rejects the concept that the BPC-157 isn’t pure. In an emailed response, he pointed to numerous papers, together with analysis from Taiwan exhibiting oblique results of BPC-157 on two receptors that promote therapeutic within the physique. And he pointed to photos from his lab that present BPC-157 in human fetal tissue cells. (Not less than one researcher was underwhelmed by these photos: “I truthfully don’t discover these knowledge convincing in any means,” wrote Brubaker, who famous that she makes use of this laboratory approach — known as immunostaining — in her personal analysis.)
As for why the early patent is scant on particulars: Folks can take it up with the U.S. patent workplace, he mentioned. (This strategy isn’t uncommon, mentioned Sherkow, the College of Illinois professor: “Folks put imprecise stuff in patent specs on a regular basis.”)
And what about publishing the amino acid sequence of the guardian protein, so others can see it? If in case you have your personal baby, Sikiric mentioned, you need it to be yours ceaselessly.
Apart from, he mentioned, the useful results converse for themselves.
He and Seiwerth estimate that between them they’ve 100 or extra present and former Ph.D. college students, a lot of them at the moment are medical college professors and lively members of their analysis workforce. Many times, in tissue samples and rodent fashions, the research report that BPC-157 works and causes few, if any, unintended effects.
For a large group of People, that’s sufficient. Some have learn the research themselves and don’t need to await permission from the FDA; some have heard glowing testimonies about BPC-157 from athletes and in style podcasters. Many say they battle with power situations and really feel poorly served by the medical system, they usually usually view the FDA as paternalistic and beholden to the profit-driven pharmaceutical trade.
These sentiments have discovered a champion in Kennedy, who has embraced experimental therapies as a part of his broader skepticism of the medical institution.
However others suppose that, for all its flaws, the FDA’s drug approval system is among the many finest on the earth. “I perceive why some within the MAHA motion are pissed off with the FDA. And I get that,” mentioned Christopher Mendias, a rehabilitation clinician-scientist at Efficiency Drugs Institute in Phoenix, Arizona. However all too usually, medication that present promise in experimental animals merely don’t carry out very properly as soon as they’re examined in people. The FDA’s present approval system helps be certain that medication are protected, and that they work, he mentioned. “Once we go round that, there’s potential penalties.”
Extra knowledge on BPC-157 could also be coming. Christopher Robinson, a regenerative drugs and ache doctor on the Johns Hopkins College Faculty of Drugs, instructed Undark that he’s making use of for funding to run scientific trials testing BPC-157 and different peptides as therapies for power ache. He’s making use of to the Superior Analysis Initiatives Company for Well being, or ARPA-H, a authorities company particularly devoted to funding high-risk, high-reward analysis that might rework well being care — or fail totally.
For now, he mentioned, individuals ought to “proceed cautiously” if contemplating taking an unapproved peptide. “I’m coming from the facet of scientists the place I want knowledge,” he mentioned. “I want professional knowledge to ensure that me to decide. I don’t need to give sufferers one thing that hasn’t been confirmed or studied considerably.” Different specialists go additional; one doctor instructed Undark earlier this yr that with out precise strong knowledge from scientific trials, BPC-157 “shouldn’t be utilized by people.”
In Croatia, Sikiric has begun to area extra calls from reporters. And he continues to work together with his present and former college students. In interviews, a number of of them mentioned they’d welcome scientific trials. This entire undertaking began a long time in the past, one in all them famous, and BPC-157 is like Sikiric’s long-gestating baby: “He must ship it.”
